Lu Quan-Yi, Wang Zhao, Li Pu, Niu Xiao-Qing, Zhang Peng, Zhao Jiang-Ning
Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2008 Aug;10(4):464-6.
At present there is no effective therapeutic approach for stage IV neuroblastoma. We report our experience with allogenic hematopoietic stem cell transplantation as a means of treating this disorder in one child.
A 7-year-old boy with stage IV neuroblastoma received allogenetic hematopoietic stem cell transplantation. The donor was his mother who was haploid HLA-matched to the patient. Conditioning regimen consisted of fludarabin and melphalan. Stem cells were collected from peripheral blood and bone marrow of the donor.
The patient achieved hematopoietic reconstruction and was converted to full donor chimerism according to short tandem repeat sequence-polymerase chain reaction detection. The patient's neutrophil count recovered to more than 0.5 x 10(9)/L 10 days after transplantation. The patient's platelet count recovered to more than 20 x 10(9)/L 11 days after transplantation. Acute graft versus host disease occurred 8 days after transplantation and was improved after treatment. The patient survived in a 210-day-follow-up.
Haploid HLA-matched allogeneic hematopoietic stem cell transplantation from parent donor was an alternative, safe and effective treatment for children with stage IV neuroblastoma.
目前对于IV期神经母细胞瘤尚无有效的治疗方法。我们报告了我们使用异基因造血干细胞移植治疗一名患有该疾病儿童的经验。
一名患有IV期神经母细胞瘤的7岁男孩接受了异基因造血干细胞移植。供者为他的母亲，与患者为单倍型HLA匹配。预处理方案包括氟达拉滨和美法仑。干细胞从供者的外周血和骨髓中采集。
根据短串联重复序列-聚合酶链反应检测，患者实现了造血重建并转变为完全供者嵌合体。患者移植后10天中性粒细胞计数恢复至超过0.5×10⁹/L。患者移植后11天血小板计数恢复至超过20×10⁹/L。移植后8天发生急性移植物抗宿主病，治疗后好转。患者在210天的随访中存活。
来自亲代供者的单倍型HLA匹配异基因造血干细胞移植是治疗IV期神经母细胞瘤儿童的一种安全有效的替代方法。
